

ProBioGen and Boehringer Ingelheim enter into Strategic Production Alliance

Berlin, April 29, 2008 - ProBioGen AG, a leading biotechnology company in mammalian and non-mammalian cell engineering and production, today announced a strategic production agreement with Boehringer Ingelheim. Under the agreement, ProBioGen will integrate some of Boehringer Ingelheim's technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production capacities. ProBioGen's clients will thereby gain access to Boehringer Ingelheim's manufacturing technology platform and large-scale commercial production. In addition, Boehringer Ingelheim's clients and partners will benefit from ProBioGen's expertise in process development and manufacturing.

„ProBioGen's strategic production alliance with Boehringer Ingelheim is an important milestone in our commercial strategy,” said Michael Schlenk, Chief Executive Officer of ProBioGen. „For one, our clients will gain access to one of the leading commercial-scale production platforms, but we will also be able to expand our client base and have started to build additional production capabilities to meet increased client demand.”

„ProBioGen's complementing services in process development and clinical material supply represent an excellent gain for Boehringer Ingelheim's worldwide strategic manufacturing network. The provision of compatible process formats and close interaction with Boehringer Ingelheim integrates state of the art and time to clinic development at ProBioGen with seamless technology transfer to Boehringer Ingelheim's commercial manufacturing”, commented Prof. Dr. Dr. h.c. Rolf G. Werner, Corporate Senior Vice President of the Corporate Division Biopharmaceuticals, Boehringer Ingelheim GmbH.

About ProBioGen AG

ProBioGen is a specialist for mammalian and non-mammalian cell engineering and production. By combining deep molecular understanding of cells with state-of-the-art industry process engineering and production know-how, ProBioGen's technologies enable biopharmaceutical companies to develop products with superior efficiency, safety and a more favourable cost profile. Since its inception in 1994, the company has processed more than 300 cell lines and established a GMP unit based on disposable reactor technology, which supports all currently available manufacturing processes. The company is headquartered in Berlin.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and nearly 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing innovative products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of almost 11 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Boehringer Ingelheim is one of the leading companies for industrial customer manufacturing of Biopharmaceuticals by offering the entire production technology chain in development and production at its biopharmaceutical facilities in Biberach (Germany) and in Vienna (Austria).

The large scale manufacturing sites deliver biopharmaceutical products like therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody fragments and plasmid DNA. The Biberach site is specialized in highly efficient mammalian cell culture systems with yields well above industry standard in animal component free media. The Austria site offers high-expression in bacteria and yeast with exceptionally high productivities using proprietary systems. In the plasmid DNA manufacturing arena Boehringer Ingelheim in Austria has set the standard and supplies early to late-stage clinical trials with gene-therapeutics and DNA vaccines for its international clients.

For more information see: <http://www.boehringer-ingelheim.com/biopharm>

Contact:

Dr. Gertraud Unterrainer, CFO

Goethestrasse 54

13086 Berlin

Tel.: +49. (0)30. 924 006-0

Fax: +49. (0)30. 924 006-19

email: info@probiogen.de